Study design. CR, complete response; DLT, dose-limiting toxicity.

<p>Study design. CR, complete response; DLT, dose-limiting toxicity.</p

Demographics and baseline characteristics of obatoclax-treated patients (N = 18).

<p>*Classified as acute promyelocytic leukemia.</p>a<p>Evaluated in 1 patient.</p>b<p>Evaluated in 2 patients.</p>c<p>Evaluated in 5 patients.</p>d<p>Evaluated in 2 patients.</p>e<p>Evaluated in 10 patients.</p><p>AML, acute myeloid leukemia; ECOG PS, Eastern Cooperative Oncology Group performance status.</p><p>Demographics and baseline characteristics of obatoclax-treated patients (N = 18).</p

Summary of dose-limiting toxicities and serious adverse events.

<p>AE, adverse event; DLT, dose-limiting toxicity (DLTs were defined as grade ≥3 infusion-related neurologic AEs and nonhematologic AEs not responsive to symptom-directed therapy); PR, probably related; PS, possibly related; NR, not related; TEAE, treatment-emergent adverse event.</p><p>Summary of dose-limiting toxicities and serious adverse events.</p

Additional file 1 of Association between abnormal lipid profile and inflammation and progression of myelodysplastic syndrome to acute leukemia

Additional file 1: Table S1. Characteristics of the laboratory tests of the patients. Table S2. Lab test characteristics stratified by the leukemia status. Table S3. Distribution of Lab values in risk subgroups. Table S4. Lab test characteristics stratified by the leukemia status for the low-risk group (n=1783). Table S5. Lab test characteristics stratified by the leukemia status for the high-risk group (n=1003

Patient disposition. AE, adverse event; CR, complete response.

<p>Patient disposition. AE, adverse event; CR, complete response.</p

HL60 (A) or OCI-AML3 cells stably expressing shRNA silencing p53 (B) were treated with Nutlin 3a for 24–96 hrs and analyzed by flow cytometry for AnnV/MDC staining.

<p>HL60 (A) or OCI-AML3 cells stably expressing shRNA silencing p53 (B) were treated with Nutlin 3a for 24–96 hrs and analyzed by flow cytometry for AnnV/MDC staining.</p

OCI-AML3 cells transduced with LC3-GFP-mCherry construct were treated with 5 μM Nutlin 3a and visualized by confocal microscopy.

<p>Increase in proportion of red ‘puncta’ at 96 hrs compared to 48 hrs (merge images) in Nutlin 3a treated cells indicate completion of autophagic flux.</p

OCI-AML3 cells were treated with Nutlin 3a for indicated time and Western blots done for p53, LC3B, Atg 5/12, p62.

<p>OCI-AML3 cells were treated with Nutlin 3a for indicated time and Western blots done for p53, LC3B, Atg 5/12, p62.</p

OCI-AML3 or REH (p53 wild type) cells stably expressing either control or Beclin1-silencing shRNA were treated with Nutlin 3a, stained with MDC and imaged with confocal microscopy for MDC positive ‘puncta’ representing autophagic vacuoles.

<p>OCI-AML3 or REH (p53 wild type) cells stably expressing either control or Beclin1-silencing shRNA were treated with Nutlin 3a, stained with MDC and imaged with confocal microscopy for MDC positive ‘puncta’ representing autophagic vacuoles.</p

OCI-AML3 (p53 wild type) or HL–60 (p53 null) cells were treated with DMSO or Nutlin 3a for 72 hours and imaged using transmission electron microscopy.

<p>While OCI-AML3 cells showed numerous electron-dense ‘mitophagic’ vacuoles at 72 hrs of Nutlin 3a treatment, such vacuoles were absent in HL–60 cells (lower panel).</p